Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Early Stage Triple-Negative Breast Carcinoma Clear all

Conditions: Triple Negative Breast Cancer, Breast Cancer
Interventions: Capecitabine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Stanford, California

Conditions: Triple Negative Breast Cancer, PD-L1 Negative
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 130
States / cities: Tucson, Arizona • Burbank, California • La Jolla, California + 92 more

Conditions: Triple Negative Breast Neoplasms
Interventions: Atezolizumab, Placebo, Gemcitabine, Capecitabine, Carboplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Paramus, New Jersey + 3 more

Conditions: Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors, Metastatic Breast Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Cancer, Recurrent Glioblastoma Multiforme, Gastric Cancer, Gastroesophageal Junction Cancer, Triple Negative Metastatic Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions: LDE225, BKM120; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Ixabepilone (Ixempra), Paclitaxel (Taxol); Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 69
States / cities: Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more

Conditions: Breast Cancer, Early-Onset
Interventions: Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more

Conditions: Breast Cancer
Interventions: Sorafenib, Cisplatin, Paclitaxel; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Interventions: Carboplatin, Paclitaxcel, Pembrolizumab; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2034
U.S. locations: 2
States / cities: Syracuse, New York • Charleston, South Carolina

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Conditions: Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer
Interventions: Cyclophosphamide, Indomethacin, Omeprazole, Multivitamin; Drug · Dietary Supplement
Lead sponsor: Providence Health & Services; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Survey Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Goodyear, Arizona • Duarte, California • Irvine, California + 2 more

Conditions: Breast Cancer, Early Stage, Triple Negative Breast Cancer
Interventions: Enzalutamide, assessment; Drug · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 12
States / cities: Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more

Conditions: Breast Cancer, Triple Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
Interventions: Nutritional Counseling; Other
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Olaparib, Capecitabine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Triple-negative Breast Cancer
Interventions: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Placebo, Nab-paclitaxel, Doxorubicin, Cyclophosphamide, Filgrastim, Pegfilgrastim; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Palo Alto, California • Norwalk, Connecticut • Carrollton, Georgia + 8 more

Conditions: Breast Cancer
Interventions: Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Columbus, Ohio • Portland, Oregon + 1 more

Conditions: Triple Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: HER2 - primed Dendritic cells, HER3 - primed Dendritic cells; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
Interventions: Paclitaxel + Carboplatin, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions: Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection; Other · Radiation · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 40 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, HER2-positive Breast Cancer, Triple Negative Breast Cancer, TNBC, Triple Negative Breast Cancer
Interventions: CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection; Diagnostic Test · Drug
Lead sponsor: Alison Stopeck; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 64
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Sargramostim; Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Seattle, Washington • Madison, Wisconsin

Conditions: Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
Interventions: There are no interventions in this observational study.; Other
Lead sponsor: Tempus AI; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 16
States / cities: Birmingham, Alabama • Whittier, California • Weston, Florida + 13 more

Conditions: Triple Negative Breast Cancer
Interventions: adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment; Biological · Device · Other
Lead sponsor: OBI Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: La Jolla, California • San Diego, California • San Francisco, California + 9 more

Search by objective public record fields.

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

TNBC Gut Microbiota During Neoadjuvant Treatment

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC